ACOR
Acorda Therapeutics, Inc. (ACOR)
$0.573
Market is closedMarket is closed – opens on 8 PM, 07 Dec 2022
– opens on 8 PM, 07 Dec 2022
Key Stats
$0.54
Day's Range
$0.5907
$0.2611
52-Week Range
$2.79
| Returns | |
| 1 month return | 9.42% |
| 3 month return | 52.84% |
| 1 year return | 78.86% |
| 5 year return | 99.54% |
Company Information
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda's innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
| Organization | Acorda Therapeutics, Inc. |
| Employees | 118 |
| CEO | Dr. Ron Cohen M.D. |
| Industry | Health Technology |
Analyst Recommendation
based on 1 analysts ratings
Buy
100%
Buy
0%
Hold
0%
Sell
Based on 1 Wall street analysts offering stock ratings for Acorda Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 1645.2%Current
$0.57
Target
$10.0
Recommendation Trend
Based on 1 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 1 | 6 | 6 |
| Hold | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 14.3M |
| Book Value | $3.11 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -8.22 |
| PEG Ratio | 0.51 |
| Wall Street Target Price | 10.0 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 0.2 |
| Enterprise Value | 187.9M |
| Enterprise Value/Revenue | 1.51 |
| Enterprise Value/Ebitda | -14.87 |
Technicals
| Beta | 1.56 |
| 50 Day MA | 0.55 |
| 200 Day MA | 0.83 |
Institutional Holdings
Davidson Kempner Capital Management LP
9.84%
Canyon Capital Advisors LLC
4.91%
Renaissance Technologies Corp
3.7%
Millennium Management LLC
1.28%
Vanguard Group Inc
0.64%
Virtu Financial LLC
0.6%
Discover more
Frequently Asked Questions
What is Acorda Therapeutics, Inc. share price today?
Can Indians buy Acorda Therapeutics, Inc. shares?
How can I buy Acorda Therapeutics, Inc. shares from India?
Can Fractional shares of Acorda Therapeutics, Inc. be purchased?
What are the documents required to start investing in Acorda Therapeutics, Inc. stocks?
What are today’s High and Low prices of Acorda Therapeutics, Inc.?
What are today’s traded volumes of Acorda Therapeutics, Inc.?
What is today’s market capitalisation of Acorda Therapeutics, Inc.?
What is the 52 Week High and Low Range of Acorda Therapeutics, Inc.?
How much percentage Acorda Therapeutics, Inc. is down from its 52 Week High?
How much percentage Acorda Therapeutics, Inc. is up from its 52 Week low?
What are the historical returns of Acorda Therapeutics, Inc.?
Who is the Chief Executive Officer (CEO) of Acorda Therapeutics, Inc.?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*